Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesVivoSim Labs, Inc.

VivoSim Labs, Inc.

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
0.1409 USD -0.00 ( 0.49%)
Last update at 2026-11-09T18:18:00Z
VOLUME
190644
Market Cap
3.65M

Momentum Score

…

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.14
Low
0.15
High
52 Week Price Range
0.26
Low
4.20
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High

Key Metrics*

Previous Close
0.14
Dividend Yield
-
Revenue TTM
0.11M
Revenue Per Share
0.03
Gross Profit TTM
-4.21M
Debt / Equity
-0.41
ROE
-343.10%
Net Debt
-4.58M
ROCE
-243.95%
Diluted EPS TTM
-4.32

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Income before tax -13.58M -2.49M -14.67M -17.26M -11.45M
Net income -13.84M -2.49M -14.67M -17.26M -11.45M
Selling general administrative 7.17M 7.69M 9.64M 9.09M 9.63M
Gross profit 0.13M 0.14M 0.11M 0.37M 1.50M
Reconciled depreciation 0.21M 0.27M 0.28M 0.29M 0.14M
Ebit - -2.48M -14.67M -17.26M -11.45M
Ebitda -13.57M -2.21M -14.39M -16.96M -11.30M
Depreciation and amortization - 0.27M 0.28M 0.29M 0.14M
Operating income -11.22M -12.62M -15.09M -17.73M -11.48M
Other operating expenses 11.36M 12.76M 15.20M 18.10M 12.98M
Interest expense 0.01M 0.01M 0.00M - -
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 0.27M 0.14M 0.41M 0.45M 0.01M
Net interest income 0.26M 0.13M 0.41M 0.45M 0.01M
Income tax expense -0.00M 0.00M 0.00M 0.00M 0.00M
Total revenue 0.13M 0.14M 0.11M 0.37M 1.50M
Total operating expenses 11.36M 12.76M 15.20M 18.10M 12.98M
Cost of revenue 0.00M 0.01M 0.00M - -
Total other income expense net -2.35M 10.13M 0.42M 0.47M 0.03M
Net income from continuing ops -13.84M -2.49M -14.67M -17.26M -11.45M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Total assets 7.39M 14.65M 6.35M 20.31M 33.30M
Other current assets 0.56M 0.79M 0.70M 0.89M 0.86M
Total liab 8.48M 4.16M 2.75M 4.98M 3.09M
Total stockholder equity -1.10M 10.49M 3.60M 15.33M 30.21M
Other current liab 1.32M 1.57M 0.73M 2.85M 0.49M
Common stock 0.00M 0.00M 0.01M 0.01M 0.01M
Capital stock 0.00M 0.00M 0.01M 0.01M 0.01M
Retained earnings -356.00M -342.16M -339.67M -325.00M -307.74M
Cash 5.02M 11.31M 2.90M 15.30M 28.68M
Total current liabilities 2.79M 3.74M 1.86M 3.67M 1.38M
Net debt -4.58M -10.37M -1.51M -13.50M -26.49M
Short term debt 0.45M 0.52M 0.51M 0.49M 0.48M
Short long term debt total 0.45M 0.94M 1.39M 1.80M 2.18M
Other stockholder equity 354.90M 352.65M 343.26M 340.32M 337.94M
Total current assets 6.63M 12.13M 3.94M 17.05M 29.53M
Short term investments - - 0.00M 0.71M 0.00M
Net receivables 1.05M 0.03M 0.03M 0.15M 0.00M
Inventory - 0.00M 0.30M 0.00M -
Accounts payable 1.02M 1.64M 0.63M 0.33M 0.41M
Accumulated other comprehensive income - - - 0.00M -
Non currrent assets other 0.15M 1.23M 0.45M 0.66M 0.95M
Non current assets total 0.76M 2.52M 2.41M 3.27M 3.76M
Capital lease obligations 0.45M 0.94M 1.39M 1.80M 2.18M
Breakdown 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Type yearly yearly yearly yearly yearly
Date 2026-03-31 2025-03-31 2024-03-31 2023-03-31 2022-03-31
Investments 0.09M 9.03M 0.82M -0.97M -0.41M
Total cashflows from investing activities 0.09M 9.03M 0.82M -0.97M -0.41M
Total cash from financing activities 4.45M 8.85M 1.44M 0.00M 0.20M
Net income -13.84M -2.49M -14.67M -17.26M -11.45M
Change in cash -6.29M 8.41M -12.40M -13.37M -8.66M
Begin period cash flow 11.46M 3.04M 15.44M 28.82M 37.48M
End period cash flow 5.17M 11.46M 3.04M 15.44M 28.82M
Total cash from operating activities -10.83M -9.46M -14.65M -12.41M -8.45M
Issuance of capital stock 4.81M 8.85M 1.44M 0.00M 0.25M
Depreciation 0.21M 0.27M 0.28M 0.29M 0.14M
Other cashflows from investing activities - 9.00M - - -
Change to inventory 0.00M -0.50M -0.30M 0.00M -
Change to account receivables -0.00M 0.00M 0.12M -0.15M 0.00M
Sale purchase of stock - - - - 0.00M
Other cashflows from financing activities - - - - -0.05M
Capital expenditures 0.00M 0.01M 0.04M 0.40M 0.41M
Change in working capital -0.68M 1.04M -2.02M 2.31M 0.60M
Stock based compensation 0.30M 0.53M 1.51M 2.38M 2.26M
Other non cash items 3.18M -8.81M 0.25M -0.12M 2.26M
Free cash flow -10.83M -9.47M -14.70M -12.80M -8.86M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
VIVS
VivoSim Labs, Inc.		 -0.00
0.49%		 0.14 - - 32.58 0.54 21.54 -0.34
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

VivoSim Labs, Inc.

VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

11555 Sorrento Valley Road, San Diego, CA, United States, 92121

858 224 1000

https://vivosim.ai

15

Name Title Year Born
Mr. Keith E. Murphy Executive Chairman & Corporate Secretary 1972
Mr. Norman Staskey President, CFO & Principal Financial Officer 1970
Dr. Amar A. Sethi M.D., Ph.D. Chief Scientific Officer 1971
Mr. Tony Lialin Chief Commercial Officer 1971

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.94
+37.96%
MOON
CAD 4.90
+11.11%
UCU
CAD 2.37
+10.75%
ANRG
CAD 1.90
+10.47%
EPRX
CAD 10.71
+10.30%
DIV
CAD 3.77
-7.37%
CSU
CAD 3281.97
-6.93%
LMN
CAD 26.62
-5.23%
TOI
CAD 99.75
-4.80%
GRZ
CAD 5.05
-4.72%

Equity Sectors*

  • Basic Materials

    +4.22%

  • Communication Services

    -0.63%

  • Consumer Cyclical

    +1.12%

  • Consumer Defensive

    +0.09%

  • Energy

    +1.91%

  • Financial Services

    +1.64%

  • Healthcare

    +1.58%

  • Industrials

    +3.56%

  • Real Estate

    +0.66%

  • Technology

    +1.84%

  • Utilities

    +1.24%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…